A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)

NCT07311551 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

112

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Dapagliflozin (10Mg Tab) along with standard medical therapy
DRUG: Empagliflozin (25 Mg Tab) along with standard medical therapy

Sponsor

Bhavya Bhavya, MD